Back to top
more

DarioHealth (DRIO)

(Delayed Data from NSDQ)

$16.35 USD

16.35
49,057

-0.92 (-5.33%)

Updated Oct 3, 2025 04:00 PM ET

After-Market: $16.41 +0.06 (0.37%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.81%
2Buy17.98%
3Hold9.90%
4Sell5.43%
5Strong Sell2.74%
S&P50011.32%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 41% (144 out of 245)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

DarioHealth Corp. (DRIO) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

DarioHealth (DRIO) delivered earnings and revenue surprises of -9.09% and -22.19%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sight Sciences (SGHT) delivered earnings and revenue surprises of +8.00% and +8.06%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

CVRx (CVRX) Reports Q2 Loss, Beats Revenue Estimates

by Zacks Equity Research

CVRx (CVRX) delivered earnings and revenue surprises of -9.62% and +0.96%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

TransMedics (TMDX) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

TransMedics (TMDX) delivered earnings and revenue surprises of +91.67% and +6.79%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

DarioHealth Corp. (DRIO) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

DarioHealth (DRIO) delivered earnings and revenue surprises of 14.29% and 10.21%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

KORU Medical Systems Inc. (KRMD) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

KORU Medical Systems Inc. (KRMD) delivered earnings and revenue surprises of -50% and 6.76%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

DarioHealth (DRIO) Upgraded to Strong Buy: Here's What You Should Know

by Zacks Equity Research

DarioHealth (DRIO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Equity Research

DarioHealth Corp. (DRIO) Reports Q3 Loss, Tops Revenue Estimates

by Zacks Equity Research

DarioHealth (DRIO) delivered earnings and revenue surprises of 27.78% and 1.13%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Zacks.com featured highlights Adverum Biotechnologies, IceCure, DarioHealth, Energous and Virgin Galactic

by Zacks Equity Research

Adverum Biotechnologies, IceCure, DarioHealth, Energous and Virgin Galactic have been highlighted in this Screen of The Week article.

Zacks Equity Research

All You Need to Know About DarioHealth (DRIO) Rating Upgrade to Strong Buy

by Zacks Equity Research

DarioHealth (DRIO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Sanghamitra Saha headshot

Bet on 5 Top-Ranked Stocks With Rising P/E

by Sanghamitra Saha

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include Adverum Biotechnologies (ADVM), IceCure Medical (ICCM), DarioHealth (DRIO), Energous (WATT) and Virgin Galactic (SPCE).

Zacks Equity Research

Zacks.com featured highlights include TAL Education, The RealReal, DarioHealth, HealthEquity and Energous

by Zacks Equity Research

TAL Education, The RealReal, DarioHealth, HealthEquity and Energous have been highlighted in this Screen of The Week article.

Sanghamitra Saha headshot

Bet on 5 Top-Ranked Stocks With Rising P/E for Stellar Gains

by Sanghamitra Saha

Tap five stocks with increasing P/E ratios. These stocks include TAL Education Group (TAL), The RealReal (REAL), DarioHealth (DRIO), HealthEquity (HQY) and Energous (WATT).

Zacks Equity Research

DarioHealth Corp. (DRIO) Q2 Earnings Beat Estimates

by Zacks Equity Research

DarioHealth (DRIO) delivered earnings and revenue surprises of 120.69% and 17.37%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

KORU Medical Systems Inc. (KRMD) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

KORU Medical Systems Inc. (KRMD) delivered earnings and revenue surprises of 50% and 12.04%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Treace Medical Concepts (TMCI) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Treace Medical Concepts (TMCI) delivered earnings and revenue surprises of -17.24% and 3.81%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

DarioHealth Corp. (DRIO) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

DarioHealth (DRIO) delivered earnings and revenue surprises of 66.10% and 3.23%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Pacific Biosciences of California (PACB) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Pacific Biosciences (PACB) delivered earnings and revenue surprises of 0% and 0.08%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

OPKO Health (OPK) Reports Q1 Loss, Misses Revenue Estimates

by Zacks Equity Research

OPKO Health (OPK) delivered earnings and revenue surprises of -33.33% and 5%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Glaukos (GKOS) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Glaukos (GKOS) delivered earnings and revenue surprises of -20.69% and 8.83%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?